Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 361–384 / 473
The ESO-T01 Phase 1 publication includes a Pregene-affiliated coauthor alongside EsoBiotec. This establishes participation in the published work, not independent ownership of ESO-T01 or a separate verified in vivo CAR-T pipeline. Commercial rights require further confirmation.
Velvet discloses amino-acid nanoparticles and minicircle DNA for in vivo CAR delivery to multiple immune-cell types. The accessible primary page does not specify a T-cell program or clinical stage; it is retained as an adjacent CAR platform rather than counted as a confirmed CAR-T developer.
Singular’s iCAR is a recombinant fusion-protein approach to modifying T or NK cells in vivo. It is kept separate from gene-encoded CAR-T because protein-based receptor installation has a different mechanism. The website does not establish human efficacy.
ImmunoVec develops programmable DNA with cell-type-specific transcriptional control; the accessible primary disclosure highlights NK cells. It is tracked as adjacent in vivo immune engineering, without assuming that CAR-NK results establish a CAR-T program or clinical stage.
Liberate’s RAPTOR delivery platform supports initial in vivo CAR-macrophage programs through monocyte/macrophage reprogramming. CAR-M is a neighboring modality, not CAR-T; these programs are not included in the confirmed CAR-T developer count.
ImmTune discloses delivery vectors for in-body cell and gene therapy. Its accessible updates are old and do not establish a current named CAR-T program or clinical status. It remains a platform watchlist entry, outside the confirmed CAR-T developer count.
Sanofi acquired Tidal in April 2021 for its nanoparticle mRNA platform for in vivo immune-cell reprogramming, including CAR-T applications. This is a historical acquired-platform record; the original preclinical description is not a verified current program stage or an independent active biotech.
Offers formulation and analytical services for small and large molecules, with publicly listed injectable solutions, suspensions, emulsions, lyophilized products, and oral formulation prototypes.
Pace Life Sciences offers Biologics analytical testing, potency and GMP quality control. This is the analytical service business of an integrated CRO/CDMO.
BioPharmaSpec offers Protein sequencing, higher-order structure, glycans and comparability. Services should be matched to the intended study and assay requirements.
Alphalyse offers Mass spectrometry, protein identification and host-cell protein analysis. Services should be matched to the intended study and assay requirements.
A CRO specializing in biologic drug products, offering early- through late-stage formulation and analytical development for high-concentration, liquid, and lyophilized products; U.S. laboratory operations were publicly disclosed in 2026.
Offers data science-assisted biologics formulation, lyophilization, and viral vector formulation services. Small-scale non-GMP production and commercial GMP manufacturing require separate confirmation.
Reading Scientific Services (RSSL) offers Biologics structure, glycans, impurities, GMP release and stability. Services should be matched to the intended study and assay requirements.
Biofidus offers Protein structure, mass spectrometry, glycans and biophysical characterization. Services should be matched to the intended study and assay requirements.
An official page explicitly offers ligand / linker design, ternary-complex prediction, mechanism / selectivity evaluation, DMPK, early CMC, solubility, crystallization, and formulation strategies.
The service page covers target / E3 ligand discovery, linker optimization, SPR/ITC, ubiquitination and degradation assays, and custom ADME and PBPK modeling.
Emery Pharma offers Biologics mass spectrometry, NMR, structural characterization and impurities. Services should be matched to the intended study and assay requirements.
Avance Biosciences offers Biologics and gene-therapy analytical testing, potency and molecular assays. Services should be matched to the intended study and assay requirements.
Texcell offers Biosafety, cell-bank characterization and bioassays. Services should be matched to the intended study and assay requirements.
Clean Cells offers Biologics potency, biosafety and cell-bank characterization. This is the analytical service business of an integrated CRO/CDMO.
Merck BioReliance offers Biologics biosafety, cell-bank characterization and GMP testing. Services should be matched to the intended study and assay requirements.
KABS Pharmaceutical Services offers Analytical development, validation and quality control for biopharmaceuticals. This is the analytical service business of an integrated CRO/CDMO.
Custom Biologics offers Biologics potency, functional assays, PK and immunogenicity. Services should be matched to the intended study and assay requirements.
Coverage expands from sourced records; this database does not claim all biopharma companies.
